BR112022020100A2 - Vacina inativada contra vírus sars-cov-2 - Google Patents

Vacina inativada contra vírus sars-cov-2

Info

Publication number
BR112022020100A2
BR112022020100A2 BR112022020100A BR112022020100A BR112022020100A2 BR 112022020100 A2 BR112022020100 A2 BR 112022020100A2 BR 112022020100 A BR112022020100 A BR 112022020100A BR 112022020100 A BR112022020100 A BR 112022020100A BR 112022020100 A2 BR112022020100 A2 BR 112022020100A2
Authority
BR
Brazil
Prior art keywords
cov
virus
vaccine against
inactivated vaccine
against sars
Prior art date
Application number
BR112022020100A
Other languages
English (en)
Inventor
Meinke Andreas
Möhlen Michael
Schlegl Robert
Heindl-Wruss Jürgen
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority claimed from PCT/EP2021/058974 external-priority patent/WO2021204825A2/en
Publication of BR112022020100A2 publication Critical patent/BR112022020100A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

VACINA INATIVADA CONTRA VÍRUS SARS-COV-2. São descritos, no presente documento, vacinas de SARS-CoV-2 e composições e métodos para produzir e administrar as ditas vacinas a indivíduos que precisam da mesma
BR112022020100A 2020-04-06 2021-04-06 Vacina inativada contra vírus sars-cov-2 BR112022020100A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202118 2020-10-15
EP20211853 2020-12-04
EP21154647 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160913 2021-03-05
PCT/EP2021/058974 WO2021204825A2 (en) 2020-04-06 2021-04-06 INACTIVATED SARS-CoV-2 VIRUS VACCINE

Publications (1)

Publication Number Publication Date
BR112022020100A2 true BR112022020100A2 (pt) 2022-11-29

Family

ID=79566178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020100A BR112022020100A2 (pt) 2020-04-06 2021-04-06 Vacina inativada contra vírus sars-cov-2

Country Status (13)

Country Link
EP (1) EP3955959A2 (pt)
JP (1) JP2023520521A (pt)
KR (1) KR20220164500A (pt)
CN (1) CN115768469A (pt)
AU (1) AU2021253605A1 (pt)
BR (1) BR112022020100A2 (pt)
CA (1) CA3168784A1 (pt)
CL (1) CL2022002365A1 (pt)
CO (1) CO2022013715A2 (pt)
EC (1) ECSP22072590A (pt)
IL (1) IL296072A (pt)
MX (1) MX2022012447A (pt)
ZA (1) ZA202209826B (pt)

Also Published As

Publication number Publication date
ECSP22072590A (es) 2022-10-31
JP2023520521A (ja) 2023-05-17
MX2022012447A (es) 2022-10-27
EP3955959A2 (en) 2022-02-23
CL2022002365A1 (es) 2023-02-03
CO2022013715A2 (es) 2022-12-30
KR20220164500A (ko) 2022-12-13
CA3168784A1 (en) 2021-10-14
ZA202209826B (en) 2023-05-31
IL296072A (en) 2022-11-01
CN115768469A (zh) 2023-03-07
AU2021253605A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
UY39159A (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
PE20151588A1 (es) Vacuna contra el virus del dengue
BRPI0813307B8 (pt) composição imunogênica, vacina, e, processo para fabricar a vacina
BR112013006396A2 (pt) composições imunogênicas
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
AR092896A1 (es) Composiciones inmunogenicas
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CY1123600T1 (el) Μεθοδος θεραπειας
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
BR112023021654A2 (pt) Vacina contra vírus

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing